SOURCE: Leerink Swann & Company

October 12, 2005 10:08 ET

Leerink Swann & Company Initiates Coverage of Endo Pharmaceuticals Holdings, Inc. (Nasdaq: ENDP)

BOSTON, MA -- (MARKET WIRE) -- October 12, 2005 -- This morning, Senior Specialty Pharmaceuticals Analyst, Gary Nachman, initiated coverage of Endo Pharmaceuticals Holdings, Inc. (NASDAQ: ENDP) with an Outperform rating. His investment rating is based on 1) the launch of oxycodone ER and Lidoderm contributing to near-term earnings growth, 2) MEDACorp survey work, which supports his bullish view of the market opportunity for oxymorphone, and 3) a product pipeline, which he considers undervalued by the Street.

About Endo Pharmaceuticals Holdings, Inc.

Endo Pharmaceuticals Holdings, Inc. (NASDAQ: ENDP) is a fully integrated specialty pharmaceutical company with market leadership in pain management, offering both branded and generic products. Its branded products include Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. Morphine sulfate, generic oxycodone hydrochloride, and acetaminophen are a few of its generic products. The company is headquartered in Chadds Ford, Pennsylvania.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2004 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp includes thousands of biomedical professionals and practicing physicians. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    John I. Fitzgerald
    Leerink Swann & Company
    (617) 918-4564